The roadmap that outlines how we live, grow and function has shifted over the past six months, altering many forward-looking plans. Despite this challenge, Sanofi continues to support the patient communities it serves—including the cancer community.
The impact of COVID-19 on people living with cancer is not small. From postponement of public screening programs to challenges receiving timely care, the impact of the pandemic on cancer patients will be felt for many years to come.
“What we need to be clear about is that we are paying a big toll, not just because of coronavirus itself, but because of the impact on current and future cancer patients and their chances of survival,” said Zsuzsanna Devecseri, Head of Global Oncology Medical Affairs.
From the early days of the pandemic, Sanofi has proactively taken steps to maintain operation of its global network of manufacturing plants and continue delivery of an uninterrupted supply of medications to patients around the world. Continuity of care is essential to ensure that people fighting cancer have the best possible chance at a positive outcome.
Sanofi is also looking toward the future, working now to ensure that clinical trials and development timelines for potential new treatment options are not derailed by the pandemic.
“Not only has Sanofi launched clinical trials to help find a solution for COVID-19, but we are also meticulously assessing our ongoing trials in oncology—working country by country, trial by trial, and investigator by investigator to identify additional product candidates,” said Peter Adamson, Global Head of Oncology Development.
Maintaining clinical trials during this pandemic is a challenge, but Sanofi has launched a multi-pronged approach to ensure continuity of this critical step in the drug development process. It has prioritized efforts to maintain drug supply and distribution, explored targeted direct-to-patient drug supply on a case-by-case basis, and used telemedicine to monitor patients remotely. This approach allowed 90% of clinical trials in China to continue during the initial COVID-19 outbreak in February.
Challenging moments require everyone to dig deeper, including Sanofi’s scientists. And they remain resilient in developing a pipeline and expanding a portfolio focused on maximizing outcomes for some of the most difficult-to-treat cancers.